Download App

Log in to access Online Inquiry
Company Overview More
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company’s Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
CEO: Casper, Marc N.
Market: NYSE
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

TMO Thermo Fisher Scientific
540.110+5.840+1.09%
Pre Mkt Price
540.11000.00%
YOY
Do not show
Hide blank lines
(Q1)2022/04/02(FY)2021/12/31(Q4)2021/12/31(Q3)2021/10/02
Assets
Current assets
Cash, cash equivalents and short term investments
-50.71% 2.75B -56.64% 4.48B -56.64% 4.48B 59.51% 12.03B
-Cash and cash equivalents
-50.71% 2.75B -56.64% 4.48B -56.64% 4.48B 59.51% 12.03B
Receivables
41.28% 8.95B 38.21% 8.95B 38.95% 7.98B 8.19% 6.37B
-Accounts receivable
42.04% 7.89B 38.95% 7.98B 38.95% 7.98B 7.15% 5.56B
-Other receivables
35.89% 1.06B 32.42% 968M -- -- 15.93% 808M
Inventory
26.28% 5.48B 25.37% 5.05B 25.37% 5.05B 28.13% 4.91B
Other current assets
11.6% 1.59B 45% 1.64B 37.7% 2.56B 45.21% 1.43B
Total current assets
6.17% 18.78B -8.4% 20.11B -8.6% 20.07B 35.59% 24.72B
Non current assets
Net PPE
37.75% 8.45B 40.95% 8.33B 40.95% 8.33B 36.08% 7.05B
-Gross PPE
-- -- 31.49% 12.59B -- -- -- --
-Accumulated depreciation
-- -- -16.23% -4.26B -- -- -- --
Goodwill and other intangible assets
54.08% 61.1B 60.19% 62.04B 60.19% 62.04B 0.48% 38.84B
-Goodwill
55.54% 41.72B 60.99% 41.92B 60.99% 41.92B 4.37% 26.91B
-Other intangible assets
51.02% 19.38B 58.56% 20.11B 58.56% 20.11B -7.33% 11.93B
Other non current assets
79.91% 4.42B 88.85% 4.64B 77.13% 4.35B 49.92% 2.99B
Total non current assets
53.32% 73.97B 59.27% 75.01B 58.66% 74.72B 6.65% 48.88B
Total assets
40.67% 92.75B 37.76% 95.12B 37.27% 94.79B 14.89% 73.6B
Liabilities
Current liabilities
Payables
24.28% 2.67B 31.82% 2.87B -- -- 35.11% 2.3B
-accounts payable
24.28% 2.67B 31.82% 2.87B -- -- 35.11% 2.3B
Current accrued expenses
35.29% 4.67B 27.12% 5.38B -- -- 14.82% 3.99B
Current debt and capital lease obligation
46550% 1.87B -3.46% 2.54B -3.46% 2.54B 850% 19M
-Current debt
46550% 1.87B -3.46% 2.54B -3.46% 2.54B 850% 19M
Current deferred liabilities
105.66% 2.87B 108.89% 2.66B -- -- 37.73% 1.44B
Other current liabilities
-- -- -- -- 40.78% 10.81B -- --
Current liabilities
72.55% 12.07B 30.4% 13.44B 29.49% 13.34B 24.49% 7.75B
Non current liabilities
Long term debt and capital lease obligation
68.39% 31.39B 69.22% 32.33B 69.22% 32.33B 2.83% 21.69B
-Long term debt
68.39% 31.39B 69.22% 32.33B 69.22% 32.33B 2.83% 21.69B
Non current deferred liabilities
85.31% 3.49B 113.88% 3.84B -- -- -4.12% 1.47B
Other non current liabilities
39.14% 4.66B 35.93% 4.54B 854.29% 48.99B 17.52% 3.98B
Total non current liabilities
65.62% 39.55B 67.94% 40.71B 235.49% 81.33B 4.34% 27.14B
Total liabilities
67.19% 51.62B 56.74% 54.15B 174.05% 94.67B 8.23% 34.89B
Shareholders'equity
Share capital
0.46% 440M 0.46% 439M -- -- 0.46% 439M
-common stock
0.46% 440M 0.46% 439M -- -- 0.46% 439M
Retained earnings
23.65% 37.53B 26.02% 35.43B -- -- 31.79% 33.88B
Paid-in capital
3.88% 16.29B 3.82% 16.17B -- -- 3.19% 15.96B
Less: Treasury stock
23.83% 10.96B 30.86% 8.92B -- -- 30.76% 8.91B
Gains losses not affecting retained earnings
8.55% -2.34B 17.03% -2.33B -- -- 10.64% -2.65B
Total stockholders'equity
16.82% 40.96B 18.22% 40.79B -- 0 21.64% 38.71B
Noncontrolling interests
-- 175M -- 184M -- 122M -- --
Total equity
17.32% 41.13B 18.75% 40.98B -99.65% 122M 21.64% 38.71B
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
--Unqualified Opinion with Explanation----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%